The Japanese POEMS syndrome with Thalidomide ( J-POST ) Trial is a phase II/III multicentre , double-blinded , randomised , controlled trial that aims to evaluate the efficacy and safety of a 24-week treatment with thalidomide in POEMS syndrome , with an additional 48-week open-label safety study .